ACTG 219C: PEDIATRIC LATE OUTCOME PROTOCOL, VERSION 30 HIV/AIDS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 描述随时间推移与HIV感染婴儿、儿童和青少年的生存、生长、神经学和神经心理功能、生活质量、器官系统毒性、代谢紊乱、潜在感染和恶性肿瘤的发展以及免疫学和病毒学参数有关的晚期结局。这还将包括对受试者接受的抗逆转录病毒和免疫治疗的潜在后遗症、青春期影响和并发症的评估。这项研究还将试图确定感染艾滋病毒的妇女所生的未感染婴儿是否因在宫内、围产期或早期婴儿期接触抗逆转录病毒治疗或免疫治疗/疫苗而表现出任何短期或长期的不良临床或实验室影响。 这是一项前瞻性的纵向研究，对围产期HIV暴露的婴儿、儿童和青少年以及患有围产期获得性感染的儿童在PACTG站点进行跟踪，无论他们是否参加PACTG方案。 这项研究的目的是描述随着时间的推移，与HIV感染的婴儿、儿童和青少年的生存、生长、神经和神经心理功能、生活质量、器官系统毒性、代谢紊乱、机会性感染和恶性肿瘤的发展以及免疫学和病毒学参数有关的晚期结局。这还将包括对受试者接受的抗逆转录病毒和免疫治疗的潜在远期结局、青春期影响和并发症的评估。此外，为了确定感染艾滋病毒的妇女所生的未受感染的婴儿是否因在宫内、围产期或早期婴儿期接触抗逆转录病毒治疗或免疫治疗/疫苗而表现出任何短期或长期的不良临床或实验室影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To describe late outcomes over time in relation to survival, growth, neurologic, and neuropsychological function, quality of life, organ system toxicity, metabolic disorders, development of oppotunistic infections and malignancies, and immunologic, and virologic parameters in HIV-infected infants, children, and adolescents. This will also include evaluation of potential late effects, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. This study will also attempt to determine if uninfected infants born to HIV-infected women demonstrate any short or long-term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy. This is a perspective, longitudinal study for long term follow-up of perinatally HIV-exposed infants, children, and adolescents, and children with post-perinatally acquired infection followed at PACTG site regardless of whether they are enrolled in PACTG protocols. The purpose of this study is to describe late outcomes over time in relation to survival, growth, neurologic and neuropsychologic function, quality of life, organ system toxicity, metabolic disorders, development of opportunistic infections and malignancies, and immunilogical, and virologic parameters in HIV-infected infants, children and adolescents. This will also include evaluation of potential late outcomes, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. Moreover, to determine if uninfected infants born to HIV-infected women demonstrate any short or long term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy.